BioPharma Dive March 24, 2025
Sponsored content By Scientist.com
To say global markets have been choppy in 2025 is an understatement. Unsurprisingly, biopharma remains one of the most dynamic sectors, driven by late-stage clinical developments, regulatory decisions and intensifying competition for novel therapies. By the end of Q2 alone, 64 Phase 3 catalysts and 43 PDUFA catalysts are anticipated, followed by another 81 Phase 3 catalysts and 69 PDUFA catalysts by the end of Q3. These and other market-moving catalysts will surely cause investors to monitor the industry closely as breakthroughs in drug development, acquisitions and FDA approvals create both opportunities and volatility.
The impact of private companies on the public market
While public companies typically dominate headlines, the novel advancements and innovations by...
Today's Sponsors
Today's Sponsor